IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Lafleur et al.

Application Serial No.: 09/487,792

Filed: January 20, 2000

Kerotinocyte Derived Interferon

1 2 2001 AR Unit: 1632

Examiner: Schnizer, R.

Attorney Docket No.: PF482P1

PROVISIONAL ELECTION UNDER 37 C.F.R. § 1.143 WITH TRAVERSE AND AMENDMENT UNDER 37 C.F.R. § 1.111

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the Office Action dated July 14, 2000, applicants provisionally elect, with traverse, Group II represented by newly added claims 41 to 177, for further prosecution. Applicants reserve the right to file one or more divisional applications directed to the nonelected inventions should the restriction requirement be made final. Applicants submit herewith the following: (a) a Petition for Extension of Time for five (5) months up to and including January 14, 2001, with appropriate fee; (b) Fee Transmittal Sheet; and (d) Supplemental Information Disclosure Statement, Form PTO/SB/08A, and copies of references AA and AB. Please amend the application as follows:

In the Specification:

On page 40, line 32, please delete "below" and insert therefor –above--.

In the Claims:

Please cancel claims 2-15, 17-21, 25, and 28-40 without prejudice.

Please add the following new claims:

√-47. (New) An isolated protein comprising a polypeptide having an amino acid sequence selected from the group consisting of:

- (a) amino acids 1 to 207 of SEQ ID NO:2;
- (b) amino acids 7 to 207 of SEQ ID NO:2;

16/2001 CCHAU1 00000130 083425 09487792